continu
atyp
coverag
mycoplasma
legionella
ad
azithromycin
thirdgener
cephalosporin
use
unusu
atyp
case
public
health
depart
contact
determin
addit
emerg
organ
present
patient
pneumonia
get
hospit
group
vulner
pneumonia
one
lead
caus
mortal
hospit
among
us
adult
studi
shown
hospit
pneumonia
rise
trend
particularli
true
among
elderli
adult
age
year
fact
particularli
relev
popul
age
life
expect
increas
elderli
repres
increas
portion
popul
elderli
thought
particularli
suscept
pneumonia
requir
hospit
higher
preval
comorbid
diseas
chronic
cardiac
pulmonari
diseas
diabet
mellitu
popul
surrog
marker
multipl
comorbid
multimorbid
also
risk
factor
pneumonia
includ
poor
perform
statu
poor
oral
hygien
high
number
invas
indwel
medic
devic
polypharmaci
box
outlin
major
risk
factor
hospit
admiss
tool
includ
factor
age
smoke
statu
pulmonari
function
valid
studi
shown
predict
longterm
risk
box
abbrevi
copd
chronic
obstruct
lung
diseas
confus
urea
respir
blood
pressur
psi
pneumonia
sever
score
pneumonia
hospit
among
adult
commun
anoth
signific
risk
factor
pneumonia
hospit
alcohol
abus
thought
due
alcohol
effect
immun
function
ciliari
surfact
function
lung
aspir
risk
malnutrit
patient
admit
hospit
subsequ
develop
hospitalacquir
pneumonia
hap
certain
popul
vulner
includ
elderli
men
structur
lung
diseas
multiorgan
system
failur
determin
patient
need
admit
hospit
versu
discharg
emerg
depart
decis
admit
patient
emerg
depart
ed
versu
pursu
outpati
treatment
import
impact
patient
outcom
patient
satisfact
complic
cost
resourc
util
exampl
studi
shown
patient
pneumonia
initi
manag
outpati
subsequ
requir
hospit
admiss
suffer
increas
risk
death
delay
recoveri
infecti
diseas
societi
america
idsa
recommend
use
patient
sever
ill
scale
guid
select
inpati
versu
outpati
treatment
varieti
sever
assess
tool
avail
physician
includ
confus
blood
urea
nitrogen
respiratori
rate
systol
blood
pressur
mm
hg
diastol
blood
pressur
mm
hg
age
adrop
age
dehydr
respiratori
failur
orient
disturb
systol
blood
pressur
pneumonia
sever
index
psi
idsaamerican
thorac
societi
at
criteria
valid
assess
pneumonia
sever
risk
mortal
tabl
fine
colleagu
articl
pneumonia
sever
index
outlin
major
score
system
use
determin
hospit
poor
outcom
acut
pneumonia
critic
tool
complex
make
less
like
use
bedsid
respons
studi
show
realtim
electron
ed
decis
support
tool
patient
pneumonia
show
improv
adher
guidelin
improv
outcom
despit
guidelin
patient
lowsever
pneumonia
frequent
admit
hospit
factor
access
ambulatori
servic
physician
person
practic
style
social
support
comorbid
diseas
includ
sever
assess
score
influenc
admiss
rate
end
physician
judgment
must
use
determin
patient
disposit
object
tool
use
aid
decis
requir
make
reliabl
diagnosi
pneumonia
diagnosi
pneumonia
base
symptom
cough
short
breath
sign
fever
leukocytosi
radiograph
find
confirm
via
microbiolog
studi
usual
obtain
issu
surround
sampl
collect
sensit
cultur
reli
symptom
sign
difficult
variabl
present
patient
factor
variat
particularli
true
elderli
often
present
atyp
symptom
often
lack
object
criteria
use
diagnosi
laboratori
radiograph
abnorm
rather
symptom
sign
pleurit
chest
pain
short
breath
cough
fever
leukocytosi
often
present
fall
decreas
function
statu
decreas
appetit
urinari
incontin
delirium
review
conclud
individu
symptom
sign
inadequ
rule
diagnosi
pneumonia
fact
combin
histori
najafi
sandrock
physic
examin
find
suffici
confirm
diagnosi
pneumonia
reli
chest
radiograph
also
signific
limit
patient
factor
includ
bodi
habitu
inspiratori
effort
comorbid
diseas
result
difficulttointerpret
radiograph
addit
studi
shown
lack
concord
radiologist
interpret
chest
radiograph
anoth
studi
highlight
delay
symptom
radiograph
find
found
half
patient
studi
admit
initi
neg
chest
radiograph
develop
radiograph
infiltr
within
hour
numer
issu
chest
radiograph
studi
look
comput
tomographi
ct
scan
aid
diagnosi
exclus
pneumonia
one
studi
found
use
ct
scan
modifi
medic
decis
twothird
case
rule
pneumonia
onethird
case
howev
costeffect
radiat
exposur
among
limit
discuss
would
need
address
chang
practic
diagnosi
pneumonia
continu
challeng
particularli
certain
popul
warrant
research
improv
method
diagnosi
allow
patient
receiv
appropri
treatment
avoid
unnecessari
advers
event
abbrevi
bun
blood
urea
nitrogen
fio
fraction
inspir
oxygen
sao
oxygen
satur
soar
systol
blood
pressur
oxygen
age
respiratori
rate
wbc
white
blood
cell
common
pathogen
implic
pneumonia
streptococcu
pneumonia
mycoplasma
pneumonia
chlamydia
pneumonia
haemophilu
influenza
legionella
speci
respiratori
virus
addit
multipl
studi
shown
staphylococcu
aureu
one
common
pneumonia
pathogen
behind
pneumonia
regard
hap
largest
report
microbiolog
hap
show
cultureposit
case
due
aureu
gramneg
pathogen
complic
factor
convent
culturebas
test
sampl
patient
suspect
hap
like
alreadi
receiv
antimicrobi
sampl
impair
sensit
pathogen
detect
use
culturebas
techniqu
addit
anoth
studi
show
respiratori
virus
commonli
isol
bacteri
organ
case
hap
one
signific
limit
studi
caus
pneumonia
pathogen
detect
case
howev
new
studi
shown
comprehens
molecular
test
significantli
increas
pathogen
detect
rate
technolog
becom
widespread
abl
develop
better
understand
microbiolog
pneumonia
box
outlin
major
organ
associ
acut
pneumonia
recommend
treatment
regimen
communityacquir
pneumonia
includ
beta
lactam
cefotaxim
ceftriaxon
ertapenem
select
patient
plu
macrolid
azithromycin
respiratori
fluoroquinolon
levofloxacin
moxifloxacin
recommend
regimen
treatment
hap
per
recent
idsa
guidelin
stratifi
patient
risk
mortal
base
need
ventilatori
support
due
pneumonia
septic
shock
likelihood
methicillinresist
aureu
mrsa
base
receipt
intraven
antibiot
within
last
day
treatment
unit
preval
mrsa
among
aureu
isol
known
prior
detect
mrsa
cultur
noncultur
screen
high
risk
mortal
low
likelihood
mrsa
treatment
one
follow
agent
recommend
piperacillintazobactam
cefepim
levofloxacin
imipenem
ertapenem
high
risk
mortal
factor
increas
likelihood
mrsa
treatment
one
follow
agent
recommend
piperacillintazobactam
cefepim
levofloxacin
ciprofloxacin
imipenem
meropenem
aztreonam
plu
vancomycin
linezolid
high
risk
mortal
receipt
intraven
antibiot
within
past
day
treatment
one
follow
agent
recommend
piperacillintazobactam
cefepim
levofloxacin
ciprofloxacin
imipenemmeropenem
amikacingentamicintobramycin
aztreonam
plu
vancomycin
linezolid
box
outlin
antibacteri
choic
base
risk
factor
patient
acut
pneumonia
identifi
individu
risk
multidrug
resist
mdr
organ
area
ongo
research
choos
appropri
initi
antibiot
regimen
paramount
import
inappropri
antibiot
choic
treatment
failur
associ
increas
mortal
length
stay
hospit
charg
although
undertr
pneumonia
lead
wors
outcom
treat
pneumonia
unnecessarili
broadspectrum
antibiot
also
lead
wors
outcom
antimicrobi
resist
clostridium
difficil
infect
confound
factor
exist
studi
may
skew
toward
higher
preval
mdr
organ
resist
organ
may
easier
grow
cultur
common
organ
pneumonia
distort
data
effort
identifi
risk
mdr
organ
idsaat
creat
health
careassoci
pneumonia
hcap
classif
includ
patient
healthi
outpati
risk
factor
macrolid
antibiot
azithromycin
clarithromycin
day
outpati
underli
ill
risk
factor
includ
underli
risk
emphysema
heart
failur
quinolon
levofloxacin
blactam
antibiot
cefpodoxim
cefuroxim
amoxicillin
amoxicillinclavulan
acid
macrolid
antibiot
azithromycin
clarithromycin
day
hospit
patient
without
multidrugresist
risk
requir
intraven
antibiot
quinolon
levofloxacin
blactam
antibiot
cefotaxim
ceftriaxon
ampicillinsulbactam
highdos
ampicillin
plu
macrolid
antibiot
azithromycin
clarithromycin
day
intensivecar
patient
sulbactam
risk
requir
intraven
antipseudomon
fluoroquinolon
levofloxacin
blactam
antibiot
cefotaxim
ceftriaxon
ampicillinsulbactam
highdos
ampicillin
plu
macrolid
antibiot
azithromycin
clarithromycin
antistaphylococc
agent
vancomycin
linezolid
recommend
patient
icu
treatment
adapt
american
thorac
societi
infecti
diseas
societi
canadian
thorac
societi
guidelin
hospit
past
day
resid
longterm
care
facil
receiv
intraven
antibiot
chemotherapi
wound
care
within
past
day
introduct
hcap
classif
use
broadspectrum
antibiot
increas
significantli
classif
come
scrutini
inconsist
abil
predict
presenc
mdr
organ
one
popul
drive
increas
use
broadspectrum
antimicrobi
nurs
home
resid
one
studi
show
patient
hospit
pneumonia
industri
countri
live
nurs
home
given
larg
increas
nurs
home
popul
better
mean
stratifi
risk
mdr
pathogen
vital
import
colleagu
found
patient
admit
pneumonia
come
nurs
home
high
risk
viral
pneumonia
emphas
need
test
respiratori
virus
allow
appropri
antibiot
stewardship
other
argu
geograph
mdr
preval
import
factor
take
account
one
studi
found
use
hcap
criteria
guid
antibiot
led
overtreat
area
low
mdr
preval
undertreat
area
high
mdr
preval
element
hcap
criteria
shown
predict
mdr
organ
particularli
receipt
intraven
antibiot
includ
recent
hap
guidelin
although
hcap
classif
may
identifi
individu
high
risk
mdr
pathogen
patient
hcap
wors
outcom
communityacquir
pneumonia
thought
due
higher
preval
comorbid
hcap
popul
anoth
group
conduct
larg
studi
found
risk
factor
mdr
organ
includ
prior
hospit
immunosuppress
previou
use
antibiot
within
last
day
use
gastric
acidsuppress
agent
tube
feed
nonambulatori
statu
suggest
risk
factor
physician
use
broadspectrum
antibiot
knowledg
field
continu
develop
hope
lead
better
antibiot
select
ultim
improv
patient
outcom
box
outlin
major
risk
factor
mdr
organ
acut
pneumonia
import
correctli
identifi
patient
pneumonia
would
benefit
icu
admiss
highlight
fact
delay
icu
transfer
sever
pneumonia
associ
increas
mortal
criteria
icu
admiss
mechan
ventil
use
vasopressor
fairli
univers
accept
beyond
criteria
guidelin
recommend
use
sever
ill
risk
mortal
determin
need
icu
admiss
end
multipl
sever
assess
avail
includ
idsaat
criteria
psi
one
limit
attempt
use
sever
score
determin
icu
admiss
heterogen
icu
admiss
criteria
differ
health
care
system
exampl
whether
noninvas
ventil
perform
floor
differ
hospit
addit
much
like
decid
outpati
inpati
treatment
mani
factor
asid
pneumonia
sever
use
determin
need
icu
admiss
idsaat
criteria
critic
valid
studi
reduct
mortal
found
patient
minor
criteria
admit
icu
anoth
studi
compar
idsaat
guidelin
psi
found
specif
sensit
respect
predict
icu
admiss
still
poor
posit
predict
valu
altern
score
systol
blood
pressur
mmhg
multilobar
chest
xray
involv
albumin
gdl
respiratori
rate
tachycardia
bpm
confus
new
onset
low
oxygen
arteri
ph
smartcop
develop
aim
predict
need
invas
respiratori
support
vasopressor
irv
univers
icu
admiss
criteria
tool
found
better
predict
need
irv
psi
accur
patient
ed
floor
anoth
studi
examin
patient
meet
icu
admiss
criteria
mechan
ventil
vasopressor
present
ed
subsequ
transfer
icu
within
first
day
admiss
identifi
baselin
characterist
independ
associ
icu
admiss
day
use
characterist
develop
predict
rule
risk
earli
admiss
intens
care
unit
reaicu
outperform
predict
rule
psi
predict
icu
admiss
day
reaicu
valid
anoth
studi
also
point
factor
high
bacteri
load
unexpect
resist
pathogen
identifi
ed
present
contribut
icu
admiss
encourag
research
inflammatori
stress
biomark
proadrenomedullin
improv
predict
tool
furthermor
studi
found
hypocapnia
hypercapnia
independ
predictor
icu
admiss
mortal
even
adjust
sever
ill
chronic
obstruct
pulmonari
diseas
encourag
use
paco
predict
tool
howev
one
studi
point
sever
score
predict
mortal
includ
mani
patient
elderli
multipl
comorbid
use
sole
tool
guid
icu
admiss
neglect
consid
whether
particular
patient
aggress
manag
strategi
appropri
end
clinic
judgment
necessari
play
import
role
sever
score
accur
enough
guid
manag
highrisk
patient
requir
icu
admiss
lowrisk
patient
discharg
ed
varieti
reason
includ
score
criteria
prevent
measur
avail
acut
pneumonia
given
high
incid
mortal
pneumonia
prevent
strategi
utmost
import
primari
mean
prevent
via
vaccin
given
pneumonia
common
pathogen
respons
pneumonia
pneumococc
vaccin
recommend
risk
includ
elderli
age
year
certain
medic
condit
vaccin
pneumococc
conjug
vaccin
shown
effect
prevent
vaccinetyp
hospit
patient
acut
pneumonia
pneumococc
pneumonia
center
diseas
control
prevent
also
recommend
influenza
vaccin
prevent
strategi
pneumonia
shown
reduc
hospit
pneumonia
influenza
well
death
anoth
studi
highlight
debat
influenza
vaccin
efficaci
elderli
secondari
tendenc
sick
frail
elderli
higher
risk
pneumonia
hospit
receiv
vaccin
frequent
rel
healthi
creat
bias
data
socal
healthi
vaccin
effect
also
ad
attempt
assess
outcom
data
influenza
vaccin
difficult
modest
vaccin
efficaci
variabl
yearli
preval
influenza
associ
respiratori
ill
statin
studi
prevent
pneumonia
found
benefici
effect
base
lowqual
data
would
benefit
studi
given
increas
role
comorbid
diseas
pneumonia
hospit
mortal
anoth
studi
suggest
focus
effort
reduc
prevent
comorbid
condit
prevent
measur
although
lot
research
ventilatorassoci
pneumonia
prevent
studi
investig
hap
prevent
chemic
oral
care
treatment
dysphagia
prevent
nosocomi
transmiss
viral
infect
univers
use
mask
earli
mobil
hand
hygien
shown
posit
result
need
studi
better
clarifi
role
efficaci
well
feasibl
implement
determin
whether
acut
pneumonia
caus
emerg
pathogen
world
public
health
critic
care
dispar
often
collid
hospit
patient
acut
pneumonia
recent
chang
viral
pneumonia
emerg
detect
particularli
pandem
highlight
need
close
contact
world
initi
case
detect
routin
surveil
sentinel
provid
provid
sent
report
back
local
state
public
health
offici
regard
caseload
influenzalik
ill
along
diagnost
sampl
subtyp
thu
sampl
return
unidentifi
subtyp
influenza
abl
determin
first
case
new
viru
addit
unusu
respiratori
virus
present
initi
sever
febril
respiratori
ill
often
respiratori
failur
icu
close
contact
critic
care
provid
public
health
offic
essenti
final
studi
illustr
close
associ
season
viral
pneumonia
influenza
respiratori
syncyti
viru
rsv
exampl
rare
present
outsid
winter
season
public
health
provid
provid
inform
critic
care
physician
allow
earli
treatment
viru
circul
addit
allow
conserv
measur
circul
final
relationship
advanc
viral
test
respiratori
secret
viru
agent
outsid
standard
multiplex
technolog
often
goe
public
health
viral
hemorrhag
fever
sever
acut
respiratori
syndrom
novel
influenza
novel
virus
appear
acut
respiratori
failur
relationship
earli
recognit
rapid
test
stress
enough
impact
respiratori
virus
critic
ill
broad
potenti
trigger
acut
respiratori
cardiac
failur
compromis
individu
potenti
protect
effect
patient
admit
icu
respiratori
heart
najafi
sandrock
failur
viru
isol
tracheobronchi
tree
nasal
lavag
gener
patient
tend
older
mean
age
year
male
higher
rate
respiratori
failur
compar
heart
failur
common
viral
isol
one
studi
rhinoviru
herp
group
influenza
anoth
studi
show
influenza
rsv
rhinoviru
common
cohort
influenza
rsv
link
wors
outcom
correct
sever
ill
rhinoviru
hand
protect
effect
independ
associ
improv
surviv
hazard
ratio
confid
interv
ci
p
howev
addit
bacteri
coinfect
seem
worsen
outcom
patient
viral
respiratori
infect
larg
cohort
critic
ill
patient
n
span
evalu
impact
viral
bacteri
coinfect
respiratori
tract
patient
subgroup
cohort
infect
viral
infect
bacteri
infect
coinfect
hospit
influenza
rsv
communityacquir
virus
associ
wors
outcom
presenc
viral
pneumonia
associ
increas
risk
pneumonia
rel
risk
rr
ci
sepsi
rr
ci
septic
shock
rr
ci
influenza
associ
increas
risk
respiratori
failur
rr
ci
adenoviru
coronaviru
group
associ
increas
risk
pneumonia
well
howev
coincid
bacteri
infect
associ
sever
outcom
especi
death
rr
ci
multiorgan
system
failur
rr
ci
septic
shock
rr
ci
compar
refer
cohort
final
interact
viral
bacteri
infect
suggest
enhanc
effect
synergi
index
ci
evalu
bacteri
coinfect
influenza
pandem
show
similar
result
among
patient
influenza
subtyp
patient
bacteri
coinfect
icu
admiss
aureu
common
follow
pneumonia
bacteri
coinfect
patient
like
present
shock
vs
p
requir
mechan
ventil
vs
p
longer
icu
stay
vs
day
median
p
higher
mortal
vs
p
immunosuppress
aureu
infect
independ
associ
higher
mortal
isol
respiratori
viru
respiratori
tract
may
associ
protect
effect
eg
rhinoviru
wors
outcom
eg
influenza
rsv
larg
depend
pathogen
isol
coinfect
bacteri
pathogen
carri
increas
risk
death
prolong
icu
stay
sepsi
multiorgan
dysfunct
compar
patient
viral
infect
particularli
influenza
rsv
combin
bacteri
infect
carri
highest
risk
death
respiratori
failur
sepsi
multiorgan
dysfunct
addit
relationship
viral
bacteri
infect
seem
enhanc
poor
outcom
increas
risk
poor
outcom
particularli
influenza
rsv
winter
viru
season
includ
earli
antivir
therapi
along
time
adequ
appropri
antibacteri
therapi
order
diminish
potenti
synergist
effect
infect
